STAT

FEBRUARY 23, 2024

meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.

264

264

World Pharma News

APRIL 16, 2024

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD).(1,2)

96

96

BioPharma Dive

OCTOBER 10, 2023

The pharma plans for the new Berkeley facility to produce clinical, and potentially commercial, supplies of a Parkinson’s disease cell therapy being tested by its subsidiary BlueRock.

111

111

STAT

MARCH 12, 2024

… Acadia Pharmaceuticals disclosed that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial , STAT tells us. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

266

266

World Pharma News

JANUARY 4, 2024

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today the completion of the 18-month data collection in the Phase Ib clinical trial for AB-1005 (AAV2-GDNF), an investigational gene therapy for treating patients with Parkinson's disease (PD).

99

99

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Gonzalez, chairman and chief executive officer of AbbVie. AbbVie also agreed a $10.1

93

93

World Pharma News

OCTOBER 11, 2023

The USD 250 million investment will support the production of material required for clinical trials and potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson's Disease.

94

94

Pharmaceutical Technology

JANUARY 22, 2024

Stem Cell Therapy for Parkinson's Disease is under clinical development by Hebei Newtherapy BIo-Pharma Technology and currently in Phase I for Parkinson's Disease.

40

40

World Pharma News

AUGUST 30, 2023

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease.

59

59

RX Note

MARCH 22, 2024

Introduction Parkinson Disease is a progressive movement disorder characterized by bradykinesia, resting tremor, muscular rigidity and loss of postural reflexes. The prevalence of Parkinson disease increases with age. Non-motor complications of Parkinson disease are major causes of disability.

Dosage 40

Dosage Communication 40

European Pharmaceutical Review

AUGUST 24, 2023

A new drug formulation of a protein kinase inhibitor therapeutic designed to modify the course of Parkinson’s diseas e has been developed. Inhibikase Therapeutics submitted two Investigational New Drug (IND) applications in February 2019 to start the clinical development in multiple classes of Parkinson’s disease patients.

88

88

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. The post BioArctic left in the cold as AbbVie abandons Parkinson’s pact appeared first on.

97

97

pharmaphorum

JUNE 7, 2022

Biogen has added a preclinical-stage drug candidate for Parkinson’s disease via a $722.5 In a statement , Biogen said that AL01811 is designed to target dysfunction in lysosomes – organelles which play a vital role in cell function by breaking down excess or worn-out cell parts and can be impaired in Parkinson’s.

Compounding 80

Compounding 80

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. Despite the interest, there have already been some failures in the alpha-synuclein category.

Immunity 98

Immunity Immunization Vaccines Drug Development 98

pharmaphorum

JULY 20, 2021

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson’s disease which is currently in early-stage clinical testing. The post FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy appeared first on.

Communication 98

Communication Immunity Immunization 98

pharmaphorum

SEPTEMBER 27, 2022

Five wearable devices that monitor patients with Parkinson’s disease as they go about their lives have been given a provisional recommendation from NICE, making them available via the NHS while additional data is collected. Main image source: Global Kinetics Corporation.

105

105

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. According to GlobalData, Phase III drugs for Parkinson’s Disease have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Drug Development 40

Drug Development 40

ALiEM - Pharm Pearls

NOVEMBER 1, 2023

What clinical presentation and medication is associated with this urinary discoloration? 6-9] Entacapone Hydroxocobalamin Levodopa Phenazopyridine Rifampin Senna Sulfasalazine Clinical Pearls Deferoxamine binds with free iron and is excreted as ferrioxamine in urine, causing a rusty discoloration known as vin rosé urine.

Clinical Pharmacology 158

Clinical Pharmacology Dosage Compounding 158

Pharmaceutical Technology

JUNE 9, 2023

MBF-015is under clinical development by Medibiofarma and currently in Phase I for Parkinson's Disease.

40

40

Med Ed 101

JUNE 3, 2020

Parkinson’s disorder can be incredibly challenging to manage. The progression of the disease and its complications can make Parkinson’s very difficult for patients and clinicians. In addition to the disease itself, medication administration in Parkinson’s can provide additional hurdles to navigate.

40

40

pharmaphorum

JULY 15, 2022

Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson’s disease candidate KW-6356, a drug in the adenosine A2A receptor antagonist class. The post Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s appeared first on.

59

59

pharmaphorum

OCTOBER 6, 2021

Last month, Astellas reported a fourth death in a trial of its AAV-based gene for X-linked myotubular myopathy (XLMTM) linked to liver damage, while another AAV therapy from BioMarin for phenylketonuria (PKU) was placed on a clinical hold after liver tumours were seen in mice given the therapy in preclinical testing.

105

105

pharmaphorum

OCTOBER 31, 2022

VRG50635 was discovered using Verge’s AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using data on DNA, RNA and protein profiles to identify new targets and drug that can interact with them. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.

Compounding 136

Compounding Drug Development 136

RX Note

JANUARY 29, 2024

Introduction Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WEB), is a common sleep-related movement disorder characterized by an often unpleasant or uncomfortable urge to move the legs that occurs during periods of inactivity , particularly in the evenings and is transiently relieved by movement. mirtazapine and SSRIs).

Mayo Clinic 52

Mayo Clinic Diabetes 52

pharmaphorum

OCTOBER 12, 2021

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson’s disease therapies to its stable. The post Supernus bulks up its Parkinson’s portfolio with Adamas takeover appeared first on. Sales were $20 million and $0.5

97

97

pharmaphorum

MARCH 12, 2021

Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep quality. . If successful, the pilot could be followed by a clinical trial programme, according to the partners.

Compounding 126

Compounding Communication 126

pharmaphorum

JANUARY 26, 2023

Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring. ” The post Roche, Boehringer tap biosensor firms for patient studies appeared first on.

Drug Development 94

Drug Development 94

Pharmaceutical Technology

JUNE 2, 2023

The drug candidate has completed a Phase IIa and Phase IIb/III clinical trial for Alzheimer’s disease, a Phase II and a Phase III trial in Rett syndrome adult patients, and a Phase II proof-of-concept trial in Parkinson’s disease.

Compounding 52

Compounding 52

European Pharmaceutical Review

MAY 16, 2023

1 Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic 1 as advanced therapy medicinal products (ATMPs). in a 2023 paper published in the Journal of Clinical Microbiology. Parkinson’s occurs when an area of the brain loses dopamine-producing nerve cells.

Hospitals 85

Hospitals 85

RX Note

APRIL 16, 2023

Introduction Nausea (the desire to vomit) and vomiting are common occurrences that can be caused by Simple disease, e.g. after exposure to bacterial toxins Motion sickness More serious underlying pathology Management When vomiting is undesirable, the first approach is to remove any precipitating factor if possible.

Clinical Pharmacology 52

Clinical Pharmacology 52

pharmaphorum

FEBRUARY 3, 2022

Since then, Biogen’s woes with Aduhelm have continued to mount, with delays to regulatory reviews in Europe and Japan and a preliminary decision in the US to limit reimbursement for the drug to patients in clinical trials. ” The post Biogen’s former R&D chief Al Sandrock resurfaces at Voyager appeared first on.

97

97

pharmaphorum

SEPTEMBER 28, 2021

It’s not the end of the line for the drug, which Biohaven picked up in 2018, after it was shelved by AstraZeneca despite reaching the phase 2 trial stage in Parkinson’s disease and MSA.

59

59

European Pharmaceutical Review

OCTOBER 17, 2022

and Parkinson’s UK’s drug development and discovery division, Parkinson’s Virtual Biotech , will collaborate on a new Phase II trial to study the effects of the drug ENT-01 on Parkinson’s Disease (PD)-associated dementia. . US biopharma company Enterin Inc. The drug ENT-01 helps to inhibit ?

Drug Development 89

Drug Development 89

pharmaphorum

MARCH 2, 2022

The total value of the deal could rise to $1 billion, dependent on whether Syndesi’s SV2A drugs – headed by early-stage clinical candidate SDI-118 – progress in development and reach the market. Syndesi is its second acquisition in the neuroscience area in the last 12 months.

52

52

pharmaphorum

AUGUST 30, 2022

The Cardiff-based company’s pipeline also includes an oral testosterone in clinical trials for hypogonadism, as well as a modified-release levothyroxine for hypothyroidism and oligonucleotide-based therapy for Cushing’s disease in preclinical development. In July, Diurnal reported product sales of around £2.3

105

105

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 9% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Drug Development 40

Drug Development 40

RX Note

OCTOBER 19, 2023

The common causes of dementia are Alzheimer disease (50 to 75% of cases) , vascular dementia (20 to 30%), frontotemporal dementias (up to 10%), and dementia with Lewy bodies and Parkinson disease dementia (up to 10%). Aducanumab was granted accelerated FDA approval for treatment of Alzheimer disease in adults in June 2021.

Diabetes 40

Diabetes 40